StemSynergy Therapeutics®
"Innovative Stem Cell Research. Targeted Cancer Therapeutics."


Notch program

Alvarez-Trotta, L. et. al. Pharmacological disruption of the Notch1 transcriptional complex inhibits tumor growth by selectively targeting cancer stem cells. Cancer Research. DOI: 10.1158/0008-5472.CAN-20-3611

Astudillo, L. et. al. The Small Molecule IMR-1 Inhibits the Notch Transcriptional Activation Complex to Suppress Tumorigenesis. Cancer Research 76, 3593-603 (2016).

FAP program

Li, B. et al. Repurposing the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis. PLoS One 9, 1-9 (2014).

Wnt program

Li, B. et al. Differential abundance of CK1alpha provides selectivity for pharmacological CK1alpha activators to target WNT-dependent tumors. Science Signaling 10, eaak9916 (2017).

Barham, W. et al. Targeting the Wnt pathway in synovial sarcoma models. Cancer Discovery 3, 1286-1301 (2013).

Xu, W. et al. The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer. PLoS One 8, 1-12 (2013).

Thorne, C.A. et al. A biochemical screen for identification of small-molecule regulators of the Wnt pathway using Xenopus egg extracts. Journal of Biomolecular Screening 16, 995-1006 (2011).

Thorne, C.A. et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nature Chemical Biology 6, 829-836 (2010).

Shh program

Rodriguez-Blanco, J. et al. A CK1alpha Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma. Clinical Cancer Research 25, 1379-1388 (2019).

Li, B. et al. Pyrvinium attenuates Hedgehog signaling downstream of Smoothened. Cancer Research 74, 4811-4821 (2014).

Scientific Team

SSTI has a multidisciplinary team of scientists.

Meet the Team


Meet the founders behind StemSynergy Therapeutics, Inc.



SSTI targets cancer stem cell pathways that drive tumor growth.

Scientific Programs